Literature DB >> 23264355

Classification criteria for Sjogren's syndrome: we actually need to definitively resolve the long debate on the issue.

Claudio Vitali1, Hendrika Bootsma, Simon J Bowman, Thomas Dorner, Jacques-Eric Gottenberg, Xavier Mariette, Manuel Ramos-Casals, Philippe Ravaud, Raphaele Seror, Elke Theander, Athanasios G Tzioufas.   

Abstract

A new approach for the classification of patients with Sjögren's syndrome (SS) has been recently proposed. Although these new criteria substantially differ from the American European Consensus Group criteria, which have represented the gold standard for the last decade, when compared with each other the two sets show a high statistical degree of agreement. However, the fact that two different criteria to classify patient with SS could be available may introduce some additional difficulties in the scientific communication, making cohorts of patients selected by using different methods less than completely equivalent, and the results of epidemiological studies and therapeutic trials not entirely comparable. Consequently, to reach a consensus agreement on universally accepted classification criteria for SS seems to be a very desirable objective.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23264355     DOI: 10.1136/annrheumdis-2012-202565

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  29 in total

1.  Downstream activation of NF-κB in the EDA-A1/EDAR signalling in Sjögren's syndrome and its regulation by the ubiquitin-editing enzyme A20.

Authors:  M Sisto; A Barca; D D Lofrumento; S Lisi
Journal:  Clin Exp Immunol       Date:  2016-02-23       Impact factor: 4.330

Review 2.  Autoantibodies in Sjögren's Syndrome.

Authors:  Anum Fayyaz; Biji T Kurien; R Hal Scofield
Journal:  Rheum Dis Clin North Am       Date:  2016-06-21       Impact factor: 2.670

3.  Rituximab-mediated Raf kinase inhibitor protein induction modulates NF-κB in Sjögren syndrome.

Authors:  Margherita Sisto; Sabrina Lisi; Massimo D'Amore; Dario D Lofrumento
Journal:  Immunology       Date:  2014-09       Impact factor: 7.397

4.  Connective tissue diseases: Refining the classification criteria for primary Sjögren syndrome.

Authors:  Arjan Vissink; Hendrika Bootsma
Journal:  Nat Rev Rheumatol       Date:  2016-12-20       Impact factor: 20.543

5.  Correlation between corneal innervation and inflammation evaluated with confocal microscopy and symptomatology in patients with dry eye syndromes: a preliminary study.

Authors:  Tudor C Tepelus; Gloria B Chiu; Jianyan Huang; Ping Huang; SriniVas R Sadda; John Irvine; Olivia L Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-05-20       Impact factor: 3.117

Review 6.  The Differential Diagnosis of Dry Eyes, Dry Mouth, and Parotidomegaly: A Comprehensive Review.

Authors:  Divi Cornec; Alain Saraux; Sandrine Jousse-Joulin; Jacques-Olivier Pers; Sylvie Boisramé-Gastrin; Yves Renaudineau; Yves Gauvin; Anne-Marie Roguedas-Contios; Steeve Genestet; Myriam Chastaing; Béatrice Cochener; Valérie Devauchelle-Pensec
Journal:  Clin Rev Allergy Immunol       Date:  2015-12       Impact factor: 8.667

7.  Unusual Sjögren's Syndrome with Bilateral Parotid Cysts.

Authors:  Bommie Florence Seo; Rock Kuen Ju; Seung-Ki Kwok; Deuk Young Oh
Journal:  Arch Craniofac Surg       Date:  2014-08-14

8.  Chronic inflammation enhances NGF-β/TrkA system expression via EGFR/MEK/ERK pathway activation in Sjögren's syndrome.

Authors:  Sabrina Lisi; Margherita Sisto; Domenico Ribatti; Massimo D'Amore; Raffella De Lucro; Maria Antonia Frassanito; Loredana Lorusso; Angelo Vacca; Dario Domenico Lofrumento
Journal:  J Mol Med (Berl)       Date:  2014-02-21       Impact factor: 4.599

9.  Prognostic value of Sjögren's syndrome autoantibodies.

Authors:  R Hal Scofield; Anum Fayyaz; Biji T Kurien; Kristi A Koelsch
Journal:  J Lab Precis Med       Date:  2018-10-30

10.  X-linked ectodermal dysplasia receptor (XEDAR) gene silencing prevents caspase-3-mediated apoptosis in Sjögren's syndrome.

Authors:  Margherita Sisto; Loredana Lorusso; Sabrina Lisi
Journal:  Clin Exp Med       Date:  2015-12-11       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.